Personal Genome Diagnostics
Personal Genome Diagnostics (PGDx) is a cancer genomics company specializing in liquid biopsy and tissue-based genomic profiling for oncology.
Profile
Develops genomic tests to detect cancer mutations from blood and tissue samples.
Personal Genome Diagnostics (PGDx) is a cancer genomics company specializing in liquid biopsy and tissue-based genomic profiling for oncology. Founded in 2010 by researchers from Johns Hopkins University, the company initially focused on developing non-invasive tests to detect cancer mutations from blood samples. PGDx's product portfolio includes clinical diagnostic tests and research tools for tumor profiling, with an emphasis on next-generation sequencing (NGS) technologies.
The company has positioned itself as a provider of comprehensive genomic analysis for both clinical and research applications, serving oncologists, pharmaceutical companies, and academic institutions. PGDx has faced competition from larger players like Guardant Health and Foundation Medicine, but its academic roots and focus on precision oncology have allowed it to carve out a niche. Recent collaborations with biopharma companies and academic centers have expanded its reach, though its financial trajectory remains closely tied to adoption rates of liquid biopsy in clinical practice. The company's most notable recent development is its involvement in large-scale cancer genome analysis projects, such as the TCGA whole-genome initiative, which aims to uncover non-coding driver mutations and structural variants.
Who buys this
- Oncologists and healthcare providers
- Pharmaceutical and biotech companies
- Academic and research institutions
- Clinical laboratories
Strengths and what to watch
Strengths
- Academic pedigree with roots in Johns Hopkins University research
- Focus on liquid biopsy, a growing segment in cancer diagnostics
- Involvement in large-scale genomic projects like TCGA
Watch for
- Competition from larger, better-funded rivals like Guardant Health
- Regulatory hurdles for liquid biopsy adoption in clinical practice
- Dependence on collaborations with biopharma for revenue
Key Information
- Founded
- 2010
Frequently Asked Questions
What does Personal Genome Diagnostics do?
Personal Genome Diagnostics (PGDx) develops genomic tests to detect cancer mutations from blood and tissue samples. Founded in 2010 by Johns Hopkins researchers, it specializes in liquid biopsy and tissue-based genomic profiling for oncology, serving clinicians, researchers, and biopharma companies with next-generation sequencing technologies.
How does PGDx's liquid biopsy work for cancer detection?
PGDx's liquid biopsy analyzes circulating tumor DNA in blood samples to identify cancer mutations non-invasively. This approach complements traditional tissue biopsies, enabling earlier detection and monitoring of tumor evolution. The technology focuses on precision oncology applications through next-generation sequencing methods.
Who uses Personal Genome Diagnostics' services?
PGDx serves oncologists, pharmaceutical companies, academic institutions, and clinical labs. Its tests support both clinical decision-making and cancer research. Key customers include healthcare providers needing diagnostic tools and biopharma firms requiring genomic data for drug development programs.
What makes PGDx different from other cancer genomics companies?
PGDx distinguishes itself through its academic roots in Johns Hopkins research and focus on comprehensive genomic analysis. While competing with larger firms like Guardant Health, it maintains a niche in precision oncology through specialized liquid biopsy tests and involvement in projects like TCGA.
What is PGDx's role in the TCGA cancer genome project?
PGDx contributes to the TCGA whole-genome initiative by analyzing non-coding driver mutations and structural variants. This collaboration with academic partners advances understanding of cancer genomics, particularly in identifying less common genetic alterations that may influence tumor behavior.
What challenges does PGDx face in the genomics market?
PGDx navigates competition from better-funded rivals, regulatory hurdles for liquid biopsy adoption, and reliance on biopharma partnerships. Its growth depends on clinical acceptance of non-invasive genomic testing and demonstrating the utility of its comprehensive profiling approach in diverse cancer types.
Sources
- techcrunch.com — Context on the genomics testing market
- www.businesswire.com — Involvement in TCGA whole-genome analysis
- www.businesswire.com — Collaboration with Broad Institute on cancer genomics
- techcrunch.com — Background on genomics cost trends